TY - JOUR
T1 - Single-cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer
AU - Pachynski, Russell K.
AU - Kim, Eric H.
AU - Miheecheva, Natalia
AU - Kotlov, Nikita
AU - Ramachandran, Akshaya
AU - Postovalova, Ekaterina
AU - Galkin, Ilia
AU - Svekolkin, Viktor
AU - Lyu, Yang
AU - Zou, Qiong
AU - Cao, Dengfeng
AU - Gaut, Joseph
AU - Ippolito, Joseph E.
AU - Bagaev, Alexander
AU - Bruttan, Maria
AU - Gancharova, Olga
AU - Nomie, Krystle
AU - Tsiper, Maria
AU - Andriole, Gerald L.
AU - Ataullakhanov, Ravshan
AU - Hsieh, James J.
N1 - Funding Information:
N. Miheecheva reports employment with BostonGene. N. Kotlov is employed by BostonGene and receives compensation as part of his employment. E. Postovalova is employed by BostonGene and receives compensation as part of her employment, and is an inventor on patent applications related to the imaging analysis technology. I. Galkin is employed by BostonGene and receives compensation as part of his employment, and is an inventor on patent applications related to the imaging analysis technology. V. Svekolkin is employed by BostonGene and receives compensation as part of his employment, and is an inventor on patent applications related to the imaging analysis technology. J.P. Gaut reports grants from NIH and grants from Mid-America Transplant Foundation outside the submitted work. A. Bagaev is employed by BostonGene and receives compensation as part of his employment, and is an inventor on patent applications related to the imaging analysis technology. M. Bruttan is employed by BostonGene and receives compensation as a part of her employment. O. Gancharova reports employment with BostonGene. K. Nomie is employed by BostonGene and receives compensation as part of her employment. M. Tsiper is employed by BostonGene and receives compensation as a part of her employment. R. Ataullakhanov is employed by BostonGene and receives compensation as part of his employment, and is an inventor on patent applications related to the imaging analysis technology. J.J. Hsieh reports grants and personal fees from BostonGene during the conduct of the study and personal fees from Eisai outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
The results shown here are in whole or part based upon data generated by TCGA Research Network: http://cancergenome.nih.gov/ and The Cancer Imaging Archive (45). This work was funded in part by a grant to Russell Pachynski (principal investigator) from the Midwest Stone Institute.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/6
Y1 - 2021/6
N2 - Purpose: Multiparametric MRI (mpMRI) has become an indispensable radiographic tool in diagnosing prostate cancer. However, mpMRI fails to visualize approximately 15% of clinically significant prostate cancer (csPCa). The molecular, cellular, and spatial underpinnings of such radiographic heterogeneity in csPCa are unclear. Experimental Design: We examined tumor tissues from clinically matched patients with mpMRI-invisible and mpMRI-visible csPCa who underwent radical prostatectomy. Multiplex immunofluorescence single-cell spatial imaging and gene expression profiling were performed. Artificial intelligence-based analytic algorithms were developed to examine the tumor ecosystem and integrate with corresponding transcriptomics. Results: More complex and compact epithelial tumor architectures were found in mpMRI-visible than in mpMRI-invisible prostate cancer tumors. In contrast, similar stromal patterns were detected between mpMRI-invisible prostate cancer and normal prostate tissues. Furthermore, quantification of immune cell composition and tumor-immune interactions demonstrated a lack of immune cell infiltration in the malignant but not in the adjacent nonmalignant tissue compartments, irrespective of mpMRI visibility. No significant difference in immune profiles was detected between mpMRI-visible and mpMRI-invisible prostate cancer within our patient cohort, whereas expression profiling identified a 24-gene stromal signature enriched in mpMRI-invisible prostate cancer. Prostate cancer with strong stromal signature exhibited a favorable survival outcome within The Cancer Genome Atlas prostate cancer cohort. Notably, five recurrences in the 8 mpMRI-visible patients with csPCa and no recurrence in the 8 clinically matched patients with mpMRI-invisible csPCa occurred during the 5-year follow-up post-prostatectomy. Conclusions: Our study identified distinct molecular, cellular, and structural characteristics associated with mpMRI-visible csPCa, whereas mpMRI-invisible tumors were similar to normal prostate tissue, likely contributing to mpMRI invisibility.
AB - Purpose: Multiparametric MRI (mpMRI) has become an indispensable radiographic tool in diagnosing prostate cancer. However, mpMRI fails to visualize approximately 15% of clinically significant prostate cancer (csPCa). The molecular, cellular, and spatial underpinnings of such radiographic heterogeneity in csPCa are unclear. Experimental Design: We examined tumor tissues from clinically matched patients with mpMRI-invisible and mpMRI-visible csPCa who underwent radical prostatectomy. Multiplex immunofluorescence single-cell spatial imaging and gene expression profiling were performed. Artificial intelligence-based analytic algorithms were developed to examine the tumor ecosystem and integrate with corresponding transcriptomics. Results: More complex and compact epithelial tumor architectures were found in mpMRI-visible than in mpMRI-invisible prostate cancer tumors. In contrast, similar stromal patterns were detected between mpMRI-invisible prostate cancer and normal prostate tissues. Furthermore, quantification of immune cell composition and tumor-immune interactions demonstrated a lack of immune cell infiltration in the malignant but not in the adjacent nonmalignant tissue compartments, irrespective of mpMRI visibility. No significant difference in immune profiles was detected between mpMRI-visible and mpMRI-invisible prostate cancer within our patient cohort, whereas expression profiling identified a 24-gene stromal signature enriched in mpMRI-invisible prostate cancer. Prostate cancer with strong stromal signature exhibited a favorable survival outcome within The Cancer Genome Atlas prostate cancer cohort. Notably, five recurrences in the 8 mpMRI-visible patients with csPCa and no recurrence in the 8 clinically matched patients with mpMRI-invisible csPCa occurred during the 5-year follow-up post-prostatectomy. Conclusions: Our study identified distinct molecular, cellular, and structural characteristics associated with mpMRI-visible csPCa, whereas mpMRI-invisible tumors were similar to normal prostate tissue, likely contributing to mpMRI invisibility.
UR - http://www.scopus.com/inward/record.url?scp=85108003763&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-4217
DO - 10.1158/1078-0432.CCR-20-4217
M3 - Article
C2 - 33771855
AN - SCOPUS:85108003763
SN - 1078-0432
VL - 27
SP - 3478
EP - 3490
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -